Blog
RSS FeedPosted by Michael Wonder on 12 Sep 2019
When are RCTs required for breakthrough drugs, HDEs? JAMA study investigates
11 September 2019 - A new study in JAMA Network Open finds that drugs and medical devices approved by the ...
Posted by Michael Wonder on 11 Sep 2019
The use of validated and non-validated surrogate endpoints in two EMA expedited approval pathways: A cross-sectional study of products authorised 2011–2018
10 September 2019 - In situations of unmet medical need or in the interests of public health, expedited approval pathways, ...
Posted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 28 Aug 2019
Patient Voice Aotearoa calls for PHARMAC reform
28 August 2019 - Patient Voice Aotearoa has launched a petition calling for the Minister of Health to initiate an ...
Posted by Michael Wonder on 27 Aug 2019
Incorporating affordability concerns within cost-effectiveness analysis for health technology assessment
27 August 2019 - New framework considers the scale, time profile, and uncertainty of budget impacts. ...
Posted by Michael Wonder on 27 Aug 2019
Pharmacists demand audit over Gliatilin’s insurance benefit
27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...
Posted by Michael Wonder on 26 Aug 2019
Developing real-world data and evidence to support regulatory decision-making
26 August 2019 - On 3 October, the FDA and the Duke-Margolis Center for Health Policy will hold a conference, ...
Posted by Michael Wonder on 21 Aug 2019
Former FDA Commissioners seek to expand use of RWE in regulatory, payment decisions
21 August 2019 - A new report from the Bipartisan Policy Center makes recommendations to expand the use of real-world ...
Posted by Michael Wonder on 21 Aug 2019
ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures
21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...
Posted by Michael Wonder on 18 Aug 2019
Lack of transparency hampers cancer drug debate
19 August 2019 - The current debate raging over cancer drug funding is emotional, and the different agenda of lobby ...
Posted by Michael Wonder on 15 Aug 2019
ICER's value framework and patient feedback: Q&A with Steve Pearson
15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...
Posted by Michael Wonder on 11 Aug 2019
The evolution of real world studies
9 August 2019 - The use of real-world evidence is evolving quickly. ...
Posted by Michael Wonder on 07 Aug 2019
DHB backs PHARMAC in making ‘hard calls’
7 August 2019 - Hauora Tairawhiti has a role of supporting drugs-funding agency PHARMAC in its ‘‘hard calls” but not ...
Posted by Michael Wonder on 29 Jul 2019
Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art
28 July 2019 - Multi-criteria decision analysis concepts, models and tools have been used increasingly in health technology assessment, with several ...
Posted by Michael Wonder on 27 Jul 2019
Stories of patient involvement impact in health technology assessments: a discussion paper
24 July 2019 - As more health technology assessment bodies seek to implement patient involvement, there is a desire to learn ...